Targeted treatments in fragile X syndrome

Expert Opinion on Orphan Drugs

Volumn 2, Issue 6, 2014, Pages 531-543

  Hare, Emma B ^a   Hagerman, Randi J ^a   Lozano, Reymundo ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

AFQ056; Arbaclofen; Fragile X mental retardation 1; Fragile X syndrome; Ganaxolone; Lovastatin; Mavoglurant; Minocycline; RO4917523; Targeted treatments

Indexed keywords

2 CHLORO 4 ((2,5 DIMETHYL 1 (4 (TRIFLUOROMETHOXY)PHENYL) 1H IMIDAZOL 4 YL)ETHYNYL)PYRIDINE; 2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; 6 QUINOXALINECARBOXYLIC ACID PIPERIDIDE; ACAMPROSATE; ARBACLOFEN; FENOBAM; GANAXOLONE; LITHIUM; MAVOGLURANT; METABOTROPIC RECEPTOR ANTAGONIST; MEVINOLIN; MG 01CI; MINOCYCLINE; NNZ 2566; ORPHAN DRUG; RG 7090; RO 4917523; STX 107; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; AUTISM; BEHAVIOR THERAPY; CLINICAL FEATURE; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FRAGILE X SYNDROME; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERPIGMENTATION; LUPUS LIKE SYNDROME; NAIL DISEASE; NERVE CELL PLASTICITY; NEUROBIOLOGY; NONHUMAN; PHENOTYPE; PHOTOSENSITIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SYMPTOMATOLOGY; TREATMENT INDICATION; TREATMENT RESPONSE;

EID: 84901314789     PISSN: None     EISSN: 21678707     Source Type: Journal    
DOI: 10.1517/21678707.2014.903795     Document Type: Review

References (98)

1. Coffee B, Keith K, Albizua I, et al. Incidence of fragile X syndrome by newborn screening for methylated FMR1 DNA. Am J Hum Genet 2009;85(4):503-14
2. Crawford DC, Acuna JM, Sherman SL. FMR1 and the fragile X syndrome: human genome epidemiology review. Genet Med 2001;3(5):359-71
3. Tassone F, Iong KP, Tong T-H, et al. FMR1 CGG allele size and prevalence ascertained through newborn screening in the united states. Genome Med 2012;4(12):100
4. Hagerman RJ, Hagerman PJ. Fragile X syndrome: diagnosis, treatment, and research. JHU Press, Baltimore; 2002
5. Roberts JE, Weisenfeld LAH, Hatton DD, et al. Social approach and autistic behavior in children with fragile X syndrome. J Autism Dev Disord 2007;37(9):1748-60
6. Sullivan K, Hatton D, Hammer J, et al. ADHD symptoms in children with FXS. Am J Med Genet A 2006;140(21):2275-88
7. Chonchaiya W, Schneider A, Hagerman RJ. Fragile X: a family of disorders. Adv Pediatr 2009;56:165-86
8. Kronk R, Bishop EE, Raspa M, et al. Prevalence, nature, and correlates of sleep problems among children with fragile X syndrome based on a large scale parent survey. Sleep 2010;33(5):679
9. Jacquemont S, Hagerman RJ, Leehey M, et al. Fragile X premutation tremor/ ataxia syndrome: molecular, clinical, and neuroimaging correlates. Am J Hum Genet 2003;72(4):869-78
10. Hagerman R, Hagerman P. Advances in clinical and molecular understanding of the fmr1 premutation and fragile X -associated tremor/ataxia syndrome. Lancet Neurol 2013;12(8):786-98
11. Sullivan SD, Welt C, Sherman S. FMR1 and the continuum of primaryovarian insufficiency. Semin Reprod Med 2011;29(4):299-307
12. Roberts JE, Bailey DB, Mankowski J, et al. Mood and anxiety disorders in females with the FMR1 premutation. Am J Med Genet B Neuropsychiatr Genet 2009;150(1):130-9
13. Bourgeois JA, Seritan AL, Casillas EM, et al. Lifetime prevalence of mood and anxiety disorders in fragile X premutation carriers. J Clin Psychiatry 2011;72(2):175
14. Hagerman P. Fragile X -associated tremor/ataxia syndrome (FXTAS): pathology and mechanisms. Acta Neuropathol 2013;126(1):1-19
15. Hessl D, Wang JM, Schneider A, et al. Decreased fragile X mental retardation protein expression underlies amygdala dysfunction in carriers of the fragile X premutation. Biol Psychiatry 2011;70(9):859-65
16. Rodriguez-Revenga L, Madrigal I, Alegret M, et al. Evidence of depressive symptoms in fragile-X syndrome premutated females. Psychiatr Genet 2008;18(4):153-5
17. Seritan AL, Bourgeois JA, Schneider A, et al. Ages of onset of mood and anxiety disorders in fragile X premutation carriers. Curr Psychiatr Rev 2013;9(1):65-71
18. Bagni C, Tassone F, Neri G, Hagerman R. Fragile X syndrome: causes, diagnosis, mechanisms, and therapeutics. J Clin Invest 2012;122(12):4314
19. Ashley CT, Wilkinson KD, Reines D, Warren ST. FMR1 protein: conserved RNP family domains and selective rna binding. Science 1993;262(5133):563-6
20. Darnell JC, Van Driesche SJ, Zhang C, et al. FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. Cell 2011;146(2):247-61
21. Iossifov I, Ronemus M, Levy D, et al. De novo gene disruptions in children on the autistic spectrum. Neuron 2012;74(2):285-99
22. Fatemi S, Folsom T, Rooney R, Thuras P. mRNA and protein expression for novel GABAA receptors q and r2 are altered in schizophrenia and mood disorders; relevance to FMRP-mGluR5 signaling pathway. Transl Psychiatry 2013;3(6):e271
23. Massey PV, Bashir ZI. Long-term depression: multiple forms and implications for brain function. Trends Neurosci 2007;30(4):176-84
24. Bear MF, Huber KM, Warren ST. The mGLuR theory of fragile X mental retardation. Trends Neurosci 2004;27(7):370-7
25. Dolen G, Carpenter RL, Ocain TD, Bear MF. Mechanism-based approaches to treating fragile X. Pharmacol Ther 2010;127(1):78-93
26. Berry-Kravis E, Knox A, Hervey C. Targeted treatments for fragile X syndrome. J Neurodev Disord 2011;3(3):193-210
27. Gross C, Nakamoto M, Yao X, et al. Excess phosphoinositide 3-kinase subunit synthesis and activity as a novel therapeutic target in fragile X syndrome. J Neurosci 2010;30(32):10624-38
28. Bhattacharya A, Kaphzan H, Alvarez-Dieppa Amanda C, et al. Genetic removal of p70 S6 kinase 1 corrects molecular, synaptic, and behavioral phenotypes in fragile X syndrome mice. Neuron 2012;76(2):325-37
29. Padgett CL, Slesinger PA. GABAB receptor coupling to g-proteins and ion channels. Adv Pharmacol 2010;58:123-47
30. Farrant M, Nusser Z. Variations on an inhibitory theme: phasic and tonic activation of GABA(A) receptors. Nat Rev Neurosci 2005;6(3):215-29
31. Cardin JA, Carlén M, Meletis K, et al. Driving fast-spiking cells induces gamma rhythm and controls sensory responses. Nature 2009;459(7247):663-7
32. Wang LW, Berry-Kravis E, Hagerman RJ. Fragile X :leading the way for targeted treatments in autism. Neurotherapeutics 2010;7(3):264-74
33. Sohal VS, Zhang F, Yizhar O, Deisseroth K. Parvalbumin neurons and gamma rhythms enhance cortical circuit performance. Nature 2009;459(7247):698-702
34. Belmonte MK, Bourgeron T. Fragile X syndrome and autism at the intersection of genetic and neural networks. Nat Neurosci 2006;9(10):1221-5
35. Rubenstein J, Merzenich M. Model of autism: increased ratio of excitation/ inhibition in key neural systems. Genes Brain Behav 2003;2(5):255-67
36. Berry-Kravis E, Grossman AW, Crnic LS, Greenough WT. Understanding fragile X syndrome. Curr Paediatr 2002;12(4):316-24
37. Hagerman RJ, Berry-Kravis E, Kaufmann WE, et al. Advances in the treatment of fragile X syndrome. Pediatrics 2009;123(1):378-90
38. Cordeiro L, Ballinger E, Hagerman R, Hessl D. Clinical assessment of dsm-iv anxiety disorders in fragile X syndrome: prevalence and characterization. J Neurodev Disord 2011;3(1):57-67
39. D'Hulst C, De Geest N, Reeve SP, et al. Decreased expression of the GABAA receptor in fragile X syndrome. Brain Res 2006;1121(1):238-45
40. lmos-Serrano JL, Paluszkiewicz SM, Martin BS, et al. Defective gabaergic neurotransmission and pharmacological rescue of neuronal hyperexcitability in the amygdala in a mouse model of fragile X syndrome. J Neurosci 2010;30(29):9929-38
41. Curia G, Papouin T, Séguéla P, Avoli M. Downregulation of tonic gabaergic inhibition in a mouse model of fragile X syndrome. Cereb Cortex 2009;19(7):1515-20
42. Adusei DC, Pacey LK, Chen D, Hampson DR. Early developmental alterations in gabaergic protein expression in fragile X knockout mice. Neuropharmacology 2010;59(3):167-71
43. Liao W-H, Van Den Abbeele T, Herman P, et al. Expression of NMDA, AMPA and GABA(A) receptor subunit mrnas in the rat auditory brainstem. II. Influence of intracochlear electrical stimulation. Hear Res 2000;150(1):12-26
44. D'Hulst C, Heulens I, Brouwer JR, et al. Expression of the gabaergic system in animal models for fragile X syndrome and fragile X associated tremor/ataxiasyndrome (FXTAS). Brain Res 2009;1253:176-83
45. Kooy FR. Of mice and the fragile X syndrome. Trends Genet 2003;19(3):148-54
46. Hagerman R, Lauterborn J, Au J, Berry-Kravis E. Fragile X syndrome and targeted treatment trials. In: Denman RB, editor, Modeling fragile X syndrome. Volume 54. Springer, Berlin Heidelberg; 2012. p. 297-335
47. Bhattacharya A, Kaphzan H, Alvarez-Dieppa AC, et al. Genetic removal of p70 S6 kinase 1 corrects molecular, synaptic, and behavioral phenotypes in fragile X syndrome mice. Neuron 2012;76(2):325-37
48. Dolen G, Osterweil E, Rao BS, et al. Correction of fragile X syndrome in mice. Neuron 2007;56(6):955-62
49. Zang JB, Nosyreva ED, Spencer CM, et al. A mouse model of the human fragile X syndrome I304n mutation. PLoS Genet 2009;5(12):e1000758
50. Dockendorff TC, Su HS, McBride SMJ, et al. Drosophila lacking dfmr1 activity show defects in circadian output and fail to maintain courtship interest. Neuron 2002;34(6):973-84
51. McBride SM, Holloway SL, Jongens TA. Using drosophila as a tool to identify pharmacological therapies for fragile X syndrome. Drug Discov Today Technol 2013;10(1):e129-36
52. Siller SS, Broadie K. Neural circuit architecture defects in a drosophila model of fragile X syndrome are alleviated by minocycline treatment and genetic removal of matrix metalloproteinase. Dis Model Mech 2011;4(5):673-85
53. Zhang YQ, Broadie K. Fathoming fragile X in fruit flies. Trends Genet 2005;21(1):37-45
54. McBride SM, Choi CH, Wang Y, et al. Pharmacological rescue of synaptic plasticity, courtship behavior, and mushroom body defects in a drosophila model of fragile X syndrome. Neuron 2005;45(5):753-64
55. Yan QJ, Rammal M, Tranfaglia M, Bauchwitz RP. Suppression of two major fragile X syndrome mouse model phenotypes by the mGluR5 antagonist MPEP. Neuropharmacology 2005;49(7):1053-66
56. de Vrij FMS, Levenga J, van der Linde HC, et al. Rescue of behavioral phenotype and neuronal protrusion morphology in fmr1 ko mice. Neurobiol Dis 2008;31(1):127-32
57. Chuang SC, Zhao W, Bauchwitz R, et al. Prolonged epileptiform discharges induced by altered group i metabotropic glutamate receptor-mediated synaptic responses in hippocampal slices of a fragile X mouse model. J Neurosci 2005;25(35):8048-55
58. Yuskaitis CJ, Mines MA, King MK, et al. Lithium ameliorates altered glycogen synthase kinase-3 and behavior in a mouse model of fragile X syndrome. Biochem Pharmacol 2010;79(4):632-46
59. Aschrafi A, Cunningham BA, Edelman GM, Vanderklish PW. The fragile X mental retardation protein and group i metabotropic glutamate receptors regulate levels of mRNA granules in brain. Proc Natl Acad Sci USA 2005;102(6):2180-5
60. Nakamoto M, Nalavadi V, Epstein MP, et al. Fragile X mental retardation protein deficiency leads to excessive mGluR5-dependent internalization of ampa receptors. Proc Natl Acad Sci USA 2007;104(39):15537-42
61. Meredith RM, de Jong R, Mansvelder HD. Functional rescue of excitatory synaptic transmission in the developing hippocampus in fmr1-ko mouse. Neurobiol Dis 2011;41(1):104-10
62. Lea PM IV, Movsesyan VA, Faden AI. Neuroprotective activity of the mGluR5 antagonists MPEP and MTEP against acute excitotoxicity differs and does not reflect actions at mGluR5 receptors. Br J Pharmacol 2005;145(4):527-34
63. Levenga J, Hayashi S, de Vrij FMS, et al. Afq056, a new mGluR5 antagonist for treatment of fragile X syndrome. Neurobiol Dis 2011;42(3):311-17
64. Michalon A, Sidorov M, Ballard TM, et al. Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice. Neuron 2012;74(1):49-56
65. Berry-Kravis E, Hessl D, Coffey S, et al. A pilot open label, single dose trial of fenobam in adults with fragile X syndrome. J Med Genet 2009;46(4):266-71
66. Jacquemont S, Curie A, des Portes V, et al. Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Sci Transl Med 2011;3(64):64ra61
67. Chang S, Bray SM, Li Z, et al. Identification of small molecules rescuing fragile X syndrome phenotypes in drosophila. Nat Chem Biol 2008;4(4):256-63
68. Paluszkiewicz SM, Martin BS, Huntsman MM. Fragile X syndrome: the gabaergic system and circuit dysfunction. Dev Neurosci 2011;33(5):349-64
69. Henderson C, Wijetunge L, Kinoshita MN, et al. Reversal of disease-related pathologies in the fragile X mouse model by selective activation of gabab receptors with arbaclofen. Sci Transl Med 2012;4(152):152ra128
70. Berry-Kravis EM, Hessl D, Rathmell B, et al. Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial. Sci Transl Med 2012;4(152):152ra127
71. Sansone SM, Widaman KF, Hall SS, et al. Psychometric study of the aberrant behavior checklist in fragile X syndrome and implications for targeted treatment. J Autism Dev Disord 2012;42(7):1377-92
72. Heulens I, D'Hulst C, Van Dam D, et al. Pharmacological treatment of fragile X syndrome with gabaergic drugs in a knockout mouse model. Behav Brain Res 2012;229(1):244-9
73. Idrissi A, Boukarrou L, Dokin C, Brown WT. Taurine improves congestive functions in a mouse model of fragile X syndrome. In: Azuma J, Schaffer S, Ito T, editors, Taurine 7. Volume 643. Springer, New York; 2009. p. 191-8
74. Erickson C, Wink L, Ray B, et al. Impact of acamprosate on behavior andbrain-derived neurotrophic factor: an open-label study in youth with fragile X syndrome. Psychopharmacology (Berl) 2013;228(1):75-84
75. Bilousova TV, Dansie L, Ngo M, et al. Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model. J Med Genet 2009;46(2):94-102
76. Michaluk P, Wawrzyniak M, Alot P, et al. Influence of matrix metalloproteinase MMP-9 on dendritic spine morphology. J Cell Sci 2011;124(19):3369-80
77. Rotschafer SE, Trujillo MS, Dansie LE, et al. Minocycline treatment reverses ultrasonic vocalization production deficit in a mouse model of fragile X syndrome. Brain Res 2012;1439:7-14
78. Utari A, Chonchaiya W, Rivera SM, et al. Side effects of minocycline treatment in patients with fragile X syndrome and exploration of outcome measures. Am J Intellect Dev Disabil 2010;115(5):433-43
79. Paribello C, Tao L, Folino A, et al. Open-label add-on treatment trial of minocycline in fragile X syndrome. BMC Neurol 2010;10(1):91
80. Leigh MJ, Nguyen DV, Mu Y, et al. A randomized double-blind, placebo-controlled trial of minocycline in children and adolescents with fragile X syndrome. J Dev Behav Pediatr 2013;34(3):147-55
81. Choi CH, McBride SM, Schoenfeld BP, et al. Age-dependent cognitive impairment in a drosophila fragile X model and its pharmacological rescue. Biogerontology 2010;11(3):347-62
82. Liu ZH, Chuang DM, Smith CB. Lithium ameliorates phenotypic deficits in a mouse model of fragile X yndrome. Int J Neuropsychopharmacol 2011;4(5):618-30
83. King MK, Jope RS. Lithium treatment alleviates impaired cognition in a mouse model of fragile X syndrome. Genes Brain Behav 2013;12(7):723-31
84. Berry-Kravis E, Sumis A, Hervey C, et al. Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome. J Dev Behav Pediatr 2008;29(4):293-302
85. Acosta MT, Kardel PG, Walsh KS, et al. Lovastatin as treatment for neurocognitive deficits in neurofibromatosis type 1: phase I study. Pediatr Neurol 2011;45(4):241-5
86. Osterweil EK, Krueger DD, Reinhold K, Bear MF. Hypersensitivity to mGluR5 and ERK1/2 leads to excessive protein synthesis in the hippocampus of a mouse model of fragile X syndrome. J Neurosci 2010;30(46):15616-27
87. Osterweil EK, Chuang S-C, Chubykin AA, et al. Lovastatin corrects excess protein synthesis and prevents epileptogenesis in a mouse model of fragile X syndrome. Neuron 2013;77(2):243-50
88. Cartagena CM, Phillips KL, Williams GL, et al. Mechanism of action for NNZ-2566 anti-inflammatory effects following PBBI involves upregulation of immunomodulator ATF3. Neuromolecular Med 2013;15(3):504-14
89. Manor I, Newcorn JH, Faraone SV, Adler LA. Efficacy of metadoxine extended release in patients with predominantly inattentive subtype attention-deficit/hyperactivity disorder. Postgrad Med 2013;125(4):181-90
90. Dziembowska M, Pretto DI, Janusz A, et al. High MMP-9 activity levels in fragile X syndrome are lowered by minocycline. Am J Med Genet A 2013;161a(8):1897-903
91. Schneider A, Leigh MJ, Adams P, et al. Electrocortical changes associated with minocycline treatment in fragile X syndrome. J Psychopharmacol 2013;27(10):956-63
92. Hagerman R, Au J, Hagerman P. FMR1 premutation and full mutation molecular mechanisms related to autism. J Neurodev Disord 2011;3(3):211-24
93. National Center for Biotechnology Information. PubChem Compound Database; CID=9926832. Available from: http://pubchem.ncbi.nlm.nih.gov/summary/summary. cgi?cid=9926832 [Accessed 15 December 2013]
94. National Center for Biotechnology Information. PubChem Compound Database; CID= 44602. Available from: http://pubchem.ncbi.nlm.nih.gov/summary/summary. cgi?cid=44602 [Accessed 15 December 2013]
95. National Center for Biotechnology Information. PubChem Compound Database; CID= 6918305. Available from: http://pubchem.ncbi.nlm.nih.gov/summary/summary. cgi?cid=6918305 [Accessed 15 December 2013]
96. National Center for Biotechnology Information. PubChem Compound Database; CID=54675783. Available from: http://pubchem.ncbi.nlm.nih.gov/summary/summary. cgi?cid=54675783 [Accessed 15 December 2013]
97. National Center for Biotechnology Information. PubChem Compound Database; CID=53232. Available from: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi? cid=53232 [Accessed 15 December 2013]
98. Berry-Kravis E, Krause SE, Block SS, et al. Effect of CX516, an AMPAmodulating compound, on cognition and behavior in fragile X syndrome: a controlled trial. J Child Adolesc Psychopharmacol 2006;16(5):525-40